|
Market Closed -
Euronext Bruxelles
16:55:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 210.60 EUR | -4.58% |
|
-2.73% | -11.74% |
| 09-01 | Global pharma companies that have publicly announced Trump drug pricing agreements | RE |
| 09-01 | White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies | MT |
| Market Cap | 40.15B 46.66B 37.78B 34.51B 64.56B 4,406B 64.74B 446B 173B 2,260B 175B 171B 7,282B | P/E 2026 * |
21x | P/E 2027 * | 17.4x |
|---|---|---|---|---|---|
| Enterprise Value | 40.46B 47.02B 38.07B 34.77B 65.05B 4,439B 65.23B 450B 175B 2,278B 177B 173B 7,338B | EV / Sales 2026 * |
4.65x | EV / Sales 2027 * | 3.96x |
| Free-Float |
61.59% | Yield 2026 * |
0.69% | Yield 2027 * | 0.71% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
Börse Stuttgart
| UNC | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
OTC Markets
| UCBJF | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript : UCB
| 1 day | -4.58% | ||
| 1 week | -2.73% | ||
| Current month | -2.18% | ||
| 1 month | -5.69% | ||
| 3 months | -18.84% | ||
| 6 months | -19.95% | ||
| Current year | -11.74% |
| 1 week | 210.6 |  | 223.2 |
| 1 month | 210.6 | | 232.9 |
| Current year | 210.6 | | 289.5 |
| 1 year | 191.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/01/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.58% | -2.73% | +2.93% | +157.71% | 48.91B | |
| -1.87% | +4.22% | +45.93% | -0.47% | 84.22B | |
| -0.57% | +0.36% | -15.55% | -35.15% | 60.48B | |
| -2.23% | +5.48% | +499.46% | +29.31% | 59.43B | |
| -2.03% | -9.22% | -7.00% | +28.39% | 50.31B | |
| -1.64% | +1.07% | +57.80% | -17.34% | 33.17B | |
| -0.98% | +1.91% | +48.35% | +95.93% | 25.95B | |
| -0.19% | -4.83% | -4.30% | +191.74% | 22.78B | |
| -1.13% | -2.78% | +62.31% | +115.55% | 16.73B | |
| -0.76% | -2.30% | +44.40% | +144.74% | 14.74B | |
| Average | -1.47% | -0.24% | +73.43% | +71.04% | 41.67B | |
| Weighted average by Cap. | -1.65% | +0.50% | +89.21% | +45.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.69B 10.1B 8.18B 7.47B 13.98B 954B 14.02B 96.67B 37.51B 489B 37.94B 37.12B 1,577B | 9.68B 11.25B 9.1B 8.32B 15.56B 1,062B 15.6B 108B 41.75B 545B 42.23B 41.31B 1,755B |
| Net income | 1.93B 2.24B 1.82B 1.66B 3.11B 212B 3.11B 21.47B 8.33B 109B 8.43B 8.24B 350B | 2.32B 2.7B 2.19B 2B 3.74B 255B 3.75B 25.85B 10.03B 131B 10.14B 9.92B 422B |
| Net Debt | 306M 355M 287M 263M 491M 33.52B 493M 3.4B 1.32B 17.2B 1.33B 1.3B 55.41B | -1.81B -2.1B -1.7B -1.55B -2.91B -198B -2.91B -20.1B -7.8B -102B -7.89B -7.72B -328B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | €210.60 | -4.58% | 312,911 |
| 03/09/26 | €220.70 | +0.09% | 205,856 |
| 02/09/26 | €220.50 | +0.92% | 202,075 |
| 01/09/26 | €218.50 | +1.49% | 200,601 |
| 31/08/26 | €215.30 | -0.55% | 312,155 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
